Baillie Gifford & Co. Sells 422,924 Shares of Guardant Health, Inc. (NASDAQ:GH)

Baillie Gifford & Co. lessened its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,449,100 shares of the company's stock after selling 422,924 shares during the period. Baillie Gifford & Co. owned 4.41% of Guardant Health worth $166,470,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in GH. Wellington Management Group LLP grew its holdings in Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock valued at $232,325,000 after buying an additional 6,618,785 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock valued at $28,128,000 after acquiring an additional 1,137,482 shares during the period. ARK Investment Management LLC grew its stake in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after acquiring an additional 1,059,104 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Guardant Health in the 3rd quarter worth about $21,389,000. Finally, Lord Abbett & CO. LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $15,624,000. Institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the company's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 2,652 shares of company stock valued at $93,192. 5.50% of the stock is currently owned by insiders.

Guardant Health Price Performance

Shares of Guardant Health stock traded down $1.60 during trading on Thursday, hitting $47.40. The company's stock had a trading volume of 3,021,831 shares, compared to its average volume of 2,470,453. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The stock has a market cap of $5.86 billion, a price-to-earnings ratio of -11.18 and a beta of 1.32. The stock has a 50-day moving average price of $40.03 and a two-hundred day moving average price of $31.51.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. On average, equities analysts predict that Guardant Health, Inc. will post -3.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on GH shares. Guggenheim reaffirmed a "buy" rating on shares of Guardant Health in a report on Wednesday, January 22nd. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $36.00 to $49.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Barclays initiated coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target for the company. Finally, Sanford C. Bernstein dropped their price target on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, October 30th. Sixteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $42.63.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.